Key takeaways
- Dividend income crosses the border: US dividend stocks give Canadian investors access to sectors and business models that simply don’t exist on the TSX, from specialty insurance to semiconductor manufacturing to biotech, and many of these companies are growing their payouts at a pace most Canadian dividend payers can’t match.
- Growth and income aren’t exclusive: The standout names on this list aren’t just paying dividends for the sake of it. They’re backed by real earnings momentum in areas like cloud networking, gold mining, and electric vehicle infrastructure, meaning you’re not sacrificing capital appreciation potential just to collect a quarterly cheque.
- Watch withholding taxes and volatility: Canadians buying US dividend stocks face a 15% withholding tax in registered accounts like TFSAs (RRSPs get a treaty exemption), which eats into your yield. On top of that, some of these sectors, particularly gold miners and smaller industrial names, can swing hard on commodity prices or shifting government policy, so position sizing matters more than usual.
Canadian investors love their dividends. I get it. The Big 6 banks, the pipelines, the telecoms. They’re familiar, they pay monthly or quarterly, and you know exactly what you own. But if dividends are your thing, limiting yourself to the TSX means you’re fishing in a pond when there’s an ocean right next door.
The U.S. market has over 4,000 publicly traded companies. The dividend payers among them span every sector imaginable, from enterprise software to gold mining to semiconductors. You get access to industries that barely exist on the TSX, and in many cases, the companies paying those dividends are growing earnings at rates that would make most Canadian blue chips jealous.
There’s a catch, obviously. Withholding tax. The IRS takes 15% of your U.S. dividend income right off the top if you hold these in a TFSA. In an RRSP, you’re exempt thanks to the Canada-U.S. tax treaty. So account placement matters a lot here. A $10,000 position yielding 3% loses $45 a year to withholding in a TFSA. Not catastrophic, but it adds up across a full portfolio. Know where you’re holding these names and why.
What I focused on for this list wasn’t just yield. Yield alone is a trap. I wanted companies with real earnings growth, reasonable valuations, and dividends that are well-covered by cash flow. A 1.5% yield from a company compounding earnings at 15% annually is a far better deal than a 5% yield from a business going nowhere. Total return is what pays for retirement, not the dividend alone.
The mix here is deliberately broad. You’ve got energy, tech, financials, healthcare, insurance. Some are large caps you’ve probably heard of. Others are small enough that most Canadian investors have never seen the ticker. That variety is the point, because the best dividend stocks don’t all cluster in the same two or three sectors.
In This Article
- AT&T Inc. (T)
- Bristol-Myers Squibb Company (BMY)
- Chevron Corporation (CVX)
- Medtronic plc (MDT)
- PepsiCo, Inc. (PEP)
- The Procter & Gamble Company (PG)
- Brookfield Asset Management Ltd. (BAM)
- Altria Group, Inc. (MO)
- The Home Depot, Inc. (HD)
- Prologis, Inc. (PLD)
AT&T Inc. (NYSE: T)
$26.14
Overall Grade7.4 / 10
AT&T Inc. operates primarily through two business segments: Communications and Latin America...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E6.9
P/B1.3
P/S1.1
P/FCF8.1
FCF Yield+12.4%
Growth & Outlook
Rev Growth (YoY)+2.6%
EPS Growth (YoY)+71.6%
Revenue 5yr-5.4%
EPS 5yr-
FCF 5yr+24.6%
Fundamentals
Market Cap$175.1B
Dividend Yield4.3%
Operating Margin+20.1%
ROE+18.3%
Interest Coverage3.6x
Competitive Edge
- AT&T's fiber footprint now passes 28M+ locations with a clear path to 50M+, creating a structural advantage over cable competitors. Fiber offers symmetrical speeds that cable's DOCSIS architecture cannot match, giving AT&T pricing power in passed markets.
- The WarnerMedia and DirecTV divestitures eliminated content risk and simplified the story into a pure-play connectivity company. This focus allows management to direct all capital toward network infrastructure rather than subsidizing media losses.
- FirstNet, the nationwide public safety broadband network, provides a sticky government contract with guaranteed spectrum priority and subscriber additions that competitors cannot replicate. This creates a durable floor under enterprise wireless revenue.
- Fixed wireless access (Internet Air) at 2.6M connections and growing 12% QoQ opens a new addressable market in areas where fiber economics don't work. This extends broadband TAM without the heavy capital cost of fiber trenching.
- Wireless spectrum holdings remain among the deepest in the industry across low, mid, and C-band frequencies. This spectrum portfolio supports 5G capacity growth without requiring the auction spending that pressured balance sheets in 2021-2022.
By the Numbers
- FCF yield of 10% with a FCF payout ratio of only 45% leaves substantial headroom for debt reduction. At $23.9B unlevered FCF against $145B net debt, the company can organically delever roughly 0.5x net debt/EBITDA per year without touching the dividend.
- Trailing P/E of 8.5x versus forward P/E of 11x appears contradictory until you realize trailing EPS of $3.04 includes one-time items, while consensus Y1 EPS of $2.34 reflects normalized earnings. The 10x valuation grade reflects genuine cheapness on a normalized basis.
- Fiber broadband connections grew 11.5% YoY to 10.4M, and total broadband net adds surged from 258K to 729K. This is the first time in years that fiber growth is more than offsetting copper losses, turning broadband from a drag into a growth contributor.
- Capex/depreciation ratio of 1.09x signals AT&T is investing just slightly above maintenance levels, meaning the heavy fiber build cycle is maturing. This should allow FCF to expand further as capex intensity declines while the fiber subscriber base monetizes.
- OCF-to-net-income of 1.73x is unusually strong, indicating high earnings quality with significant non-cash depreciation flowing through. Combined with FCF/NI of 0.76x after heavy capex, the cash generation engine is real, not accounting-driven.
Risk Factors
- Postpaid phone churn spiked to 0.90% from 0.76% YoY, an 18.4% increase, while postpaid net adds fell 22.8% to 1.74M. This churn deterioration in the highest-value subscriber category is a leading indicator of competitive pressure from T-Mobile and pricing fatigue.
- Tangible book value per share is negative $12.55, driven by intangibles comprising 46.5% of total assets and goodwill at 14.9%. The $1.59 P/B ratio is misleading because it rests on $67B+ of intangible assets that could face impairment if business wireline declines accelerate.
- Business wireline revenue declined 8.4% YoY to $17.2B, accelerating from the prior year's 9.9% decline. This segment has shrunk from $24B to $17B in four years, a $7B annual revenue hole that mobility and fiber must fill just to keep the company flat.
- Current ratio of 0.97x and quick ratio of 0.49x indicate AT&T cannot cover short-term obligations with liquid assets. With $163B total debt and a debt grade of 4.6/10, any disruption to capital markets access during refinancing windows creates real liquidity risk.
- Prepaid subscriber net adds turned sharply negative at -536K, a 425% deterioration YoY. Prepaid is a leading indicator of competitive positioning in the value segment, and this loss suggests Cricket is losing ground to T-Mobile's Metro and Verizon's Visible brands.
Bristol-Myers Squibb Company (NYSE: BMY)
$63.42
Overall Grade7.2 / 10
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, and markets prescription medicines for serious diseases. The company focuses on key therapeutic areas including oncology, hematology, immunology, and cardiovascular disease...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E12.7
P/B5.3
P/S2.4
P/FCF10.3
FCF Yield+9.7%
Growth & Outlook
Rev Growth (YoY)+3.1%
EPS Growth (YoY)+83.1%
Revenue 5yr+2.1%
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$130.2B
Dividend Yield4.0%
Operating Margin+23.8%
ROE+46.6%
Interest Coverage-
Competitive Edge
- Eliquis co-promotion with Pfizer creates a unique distribution advantage in anticoagulants, with switching costs embedded in physician prescribing habits and patient INR management protocols. Generic entry faces complex formulation and regulatory hurdles.
- BMY's immuno-oncology franchise (Opdivo, Yervoy) benefits from expanding label indications and combination regimens. Each new indication creates clinical data that reinforces physician adoption, building a compounding evidence moat.
- The Celgene acquisition brought Revlimid's cash flows and, critically, the CAR-T platforms (Abecma, Breyanzi) that position BMY in next-generation cell therapy, a market with high barriers to entry due to manufacturing complexity.
- BMY's cardiovascular and immunology pipeline (milvexian, cendakimab) targets large addressable markets. Milvexian as a Factor XIa inhibitor could be a differentiated anticoagulant with lower bleeding risk, a genuine clinical advance over current standards.
- Regulatory capture through decades of FDA engagement gives BMY institutional knowledge in navigating approval pathways. This is a durable but invisible advantage that reduces development timelines and increases probability of approval versus smaller competitors.
By the Numbers
- Forward P/E of 9.7x vs trailing 17.4x implies consensus expects EPS to nearly double from $3.46 to $6.34, and the PEG of 0.12 suggests the market is dramatically underpricing that earnings inflection relative to growth.
- FCF margin of 24.6% significantly exceeds net margin of 15.0%, with FCF-to-net-income conversion at 1.64x. This signals high earnings quality, as cash generation substantially outpaces reported profits, likely due to large non-cash amortization of acquired intangibles.
- FCF payout ratio of 42.7% vs earnings payout ratio of 69.7% reveals the dividend is far more secure than the income statement suggests. The gap reflects heavy intangible amortization depressing GAAP earnings while cash flow remains strong.
- Total shareholder yield of 13.1% is exceptional, driven primarily by 9.0% debt paydown yield. Management is aggressively deleveraging from the Celgene acquisition, which directly reduces equity risk and improves the capital structure.
- R&D spending at 28.8% of revenue ($13.9B) is among the highest in large-cap pharma, funding pipeline replenishment against upcoming LOEs. This is not discretionary cost but essential investment that the 24.6% FCF margin still comfortably supports.
Risk Factors
- Analyst revenue estimates project a decline from $47.4B (Y1) to $36.8B (Y5), a 22% cumulative drop. This reflects the Eliquis and Opdivo patent cliff, and the Growth grade of 3.5/10 confirms the market sees this as a structurally shrinking top line.
- FCF has deteriorated sharply: 3-year CAGR of -28.1% and 5-year CAGR of -19.4%. Even with strong current FCF margins, the trajectory is clearly negative, and the -40.1% YoY FCF decline in the most recent period is alarming.
- Net debt of $34B at 2.5x EBITDA with a Debt grade of 3.0/10 is concerning given the revenue cliff ahead. As EBITDA contracts with patent expirations, this leverage ratio will mechanically worsen unless debt paydown accelerates.
- Tangible book value per share is negative at -$9.76, with intangibles comprising 46.2% and goodwill 25.1% of total assets. This $62 stock is entirely supported by earnings power from assets that face binary pipeline and patent risk.
- EPS estimates decline from $6.34 (Y1) to $4.78 (Y5), a 25% erosion. The current forward P/E of 9.7x looks cheap until you realize you are buying a declining earnings stream, not a stable one.
Chevron Corporation (NYSE: CVX)
$213.18
Overall Grade7.2 / 10
Chevron Corporation is a leading integrated energy and chemicals company with operations spanning the globe. The company's business is divided into two primary segments: Upstream and Downstream...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E15.9
P/B1.7
P/S1.6
P/FCF12.1
FCF Yield+8.2%
Growth & Outlook
Rev Growth (YoY)+11.2%
EPS Growth (YoY)+34.2%
Revenue 5yr+12.5%
EPS 5yr+41.0%
FCF 5yr+13.7%
Fundamentals
Market Cap$420.4B
Dividend Yield3.3%
Operating Margin+12.2%
ROE+12.2%
Interest Coverage17.9x
Competitive Edge
- The Hess acquisition gives Chevron a 30% stake in Guyana's Stabroek block, one of the world's lowest-cost, highest-return oil developments. With breakevens below $35/bbl, this asset generates strong returns even in a downturn and adds decades of reserve life.
- Chevron's Permian Basin position (over 700K MBOED) benefits from multi-bench development and proximity to Gulf Coast export infrastructure. Unlike smaller E&Ps, Chevron can self-fund Permian growth within cash flow at $60 Brent, eliminating the need for external capital.
- LNG exposure through Gorgon, Wheatstone, and the expanding portfolio provides structural demand growth as Asian and European buyers sign long-term contracts. LNG pricing is increasingly oil-indexed, giving Chevron a natural hedge against gas-specific volatility.
- Lowest SG&A-to-revenue ratio (2.6%) among supermajors reflects genuine operational discipline. This is structural, not cyclical, and provides margin resilience that peers like BP and Shell cannot match at equivalent commodity prices.
- Chevron's balance sheet (0.19x debt-to-equity, 0.58x net debt-to-EBITDA) is the strongest among integrated peers, giving it optionality to acquire counter-cyclically or sustain shareholder returns through a prolonged downturn without cutting the dividend.
By the Numbers
- PEG of 0.33 against a forward P/E of 13.57 implies the market is pricing in almost no growth, yet consensus EPS jumps from $6.63 trailing to $15.89 in Y1, a 140% increase largely reflecting the Hess acquisition fully flowing through. That gap is unusually wide for a supermajor.
- Total upstream production grew 11.5% YoY to 3,723 MBOED in FY2025, with U.S. production surging 16.2% to 1,858 MBOED. This volume growth is running well ahead of capex growth (upstream capex up only 10.9%), signaling improving capital efficiency from Permian and DJ Basin assets.
- FCF-to-net-income ratio of 1.29x confirms earnings quality is strong. Cash generation exceeds reported profits, and OCF covers total debt 1.22x annually, meaning Chevron could theoretically retire all debt in under a year from operating cash flow alone.
- Total shareholder yield of 6.7% (4.2% dividend, 2.5% buyback, 0.7% debt paydown) is among the highest in the integrated oil peer group, and the FCF payout ratio of 51% leaves meaningful headroom to sustain this even if oil prices soften $10-15/bbl.
- Capex-to-depreciation of 0.78x means Chevron is spending less than its depreciation charge, effectively harvesting its asset base. Combined with 16% production growth, this suggests the Hess and PDC acquisitions are delivering volumes without proportional incremental capital.
Risk Factors
- Upstream international segment earnings fell 36.3% YoY to $7B despite international production rising 7.2% to 1,865 MBOED. Revenue per BOE is compressing sharply, likely reflecting weaker Brent realizations and unfavorable PSC effects as oil prices decline.
- Share count grew 6.5% YoY, the Hess stock deal dilution. At $9.9B in TTM buybacks, Chevron is spending heavily but only partially offsetting this dilution. Revenue per share ($105.62) will take years to recover to pre-dilution levels at current buyback pace.
- Operating margin of 12.2% and net margin of 10% are well below mid-cycle norms for integrated oils (typically 15-18% operating). The 'All Other' segment drag widened to negative $3.5B, up 33% YoY, suggesting rising corporate costs, integration expenses, or hedging losses.
- Downstream U.S. earnings collapsed 86% in FY2024 to $531M before rebounding to $1.4B in FY2025. This volatility, combined with downstream capex being slashed 45% YoY, suggests Chevron is underinvesting in refining just as crack spreads normalize. Deferred maintenance risk is real.
- 3-year EPS CAGR is negative 2.8% and 3-year revenue CAGR is under 2%, reflecting that the 2022 commodity windfall has fully unwound. The growth grade of 6.4/10 confirms this is not a growth story at current commodity prices.
Medtronic plc (NYSE: MDT)
$90.56
Overall Grade6.8 / 10
Founded in 1949 as a medical equipment repair shop, Medtronic has grown into a diversified medical technology leader. The company operates through four primary business segments: the Cardiovascular Portfolio, the Medical Surgical Portfolio, the Neuroscience Portfolio, and the Diabetes Operating Unit...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E21.0
P/B2.2
P/S2.9
P/FCF17.8
FCF Yield+5.6%
Growth & Outlook
Rev Growth (YoY)+9.8%
EPS Growth (YoY)+11.8%
Revenue 5yr+3.5%
EPS 5yr+7.3%
FCF 5yr-0.3%
Fundamentals
Market Cap$117.2B
Dividend Yield3.2%
Operating Margin+18.1%
ROE+10.6%
Interest Coverage9.4x
Competitive Edge
- Medtronic's PulseSelect pulsed field ablation system is a genuine category creator in cardiac ablation, offering tissue selectivity that thermal ablation cannot match. This technology is driving the 17.4% Cardiac Rhythm acceleration and represents a multi-year replacement cycle opportunity.
- The Hugo robotic surgical system positions MDT as the only credible scaled competitor to Intuitive Surgical in soft-tissue robotics. Unlike J&J's Ottava (still pre-launch), Hugo is already generating clinical data and building an installed base internationally.
- Medtronic's 50/50 U.S./international revenue split provides natural diversification that peers like Boston Scientific (65% U.S.) lack. Emerging markets grew 6.5% in FY2025, providing a structural growth tailwind as hospital infrastructure expands in India, China, and Southeast Asia.
- Regulatory moat is deep: FDA PMA approvals for Class III implantable devices take 3-5 years and $50-100M+ to obtain. Medtronic holds thousands of these approvals across cardiac, neuro, and spine, creating switching costs that lock in hospital purchasing committees for years.
- The insulin pump installed base creates recurring consumable revenue (infusion sets, reservoirs, sensors) with 80%+ gross margins. As the 780G system regains share, each new pump placement generates 5-7 years of high-margin consumable pull-through.
By the Numbers
- PEG of 0.33 is exceptionally low for a mega-cap medtech name, with forward P/E of 15.76x implying 60% earnings growth from trailing $3.73 to estimated $5.97 in Y1. That gap suggests a significant earnings step-up the market hasn't fully priced.
- FCF-to-net-income conversion of 1.16x confirms high earnings quality. OCF-to-net-income of 1.52x shows depreciation and amortization are real cash-generating assets, not just accounting noise from the Covidien acquisition goodwill stack.
- Cardiac Rhythm & Heart Failure revenue accelerated from 3.7% to 6.6% to 17.4% YoY growth over FY2024-FY2026, reaching $7.5B. This segment alone added $1.1B in revenue in FY2026, likely driven by the Micra leadless pacemaker and PulseSelect PFA system gaining share.
- Diabetes segment posted three consecutive years of accelerating organic growth (2.4% to 8.6% to 11.5%), with revenue hitting $3.1B. The MiniMed 780G system is clearly regaining competitive ground against Insulet and Dexcom in the closed-loop insulin delivery market.
- Total shareholder yield of 3.65% (3.3% dividend plus 0.6% buyback plus debt paydown) is solid for a company still investing in growth. SBC at 1.3% of revenue is modest for a $36B revenue company, meaning buybacks are genuinely reducing share count rather than just offsetting dilution.
Risk Factors
- All three major segment operating profits collapsed in FY2026: Cardiovascular down 23.5%, Neuroscience down 26.8%, Medical Surgical down 30%. Revenue grew 12%, 4.5%, and 4.9% respectively, meaning margin compression was severe and broad-based, not isolated to one business.
- Tangible book value per share is negative $2.48, with goodwill and intangibles comprising 57% of total assets ($46B+). This is the lingering Covidien acquisition overhang. Any impairment write-down would crater book value and ROE simultaneously.
- Cash conversion cycle of 157 days is extremely long, with days inventory outstanding at 168 days. Inventory turnover of just 2.17x means MDT is carrying roughly six months of inventory, tying up working capital and raising obsolescence risk in a product cycle-driven business.
- Five-year FCF CAGR is slightly negative at -0.3% despite 3.5% revenue CAGR over the same period. FCF margin of 16.3% looks healthy in isolation, but the inability to grow absolute free cash flow over five years while revenue expanded $5B+ signals structural cost absorption.
- Operating margin of 18.1% sits well below gross margin of 65%, with SG&A consuming 32.4% of revenue. That 47-point spread between gross and operating margin is wide even for medtech, suggesting the direct sales force and global distribution infrastructure are a permanent cost drag.
PepsiCo, Inc. (NASDAQ: PEP)
$136.41
Overall Grade6.6 / 10
PepsiCo, Inc. is a multinational food, snack, and beverage corporation headquartered in Purchase, New York...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E18.9
P/B8.9
P/S2.0
P/FCF21.2
FCF Yield+4.7%
Growth & Outlook
Rev Growth (YoY)+5.6%
EPS Growth (YoY)+39.0%
Revenue 5yr+5.4%
EPS 5yr+5.2%
FCF 5yr+5.4%
Fundamentals
Market Cap$186.5B
Dividend Yield4.3%
Operating Margin+14.8%
ROE+51.5%
Interest Coverage12.7x
Competitive Edge
- PepsiCo's dual snack-and-beverage model creates unique cross-selling leverage with retailers that pure-play competitors like Coca-Cola or Mondelez cannot replicate, giving PepsiCo superior shelf-space negotiating power and distribution efficiency.
- The FY2025 segment restructuring (merging Frito-Lay and Quaker into PFNA, creating IB Franchise) signals management is moving toward a franchise-heavy international beverage model, which is capital-light and should improve ROIC over time.
- Frito-Lay's dominance in U.S. salty snacks (60%+ share) creates a near-monopoly position with switching costs embedded in retailer planograms and consumer habits, making this the highest-quality asset in the consumer staples universe.
- GLP-1 weight loss drug adoption could disproportionately benefit PepsiCo's zero-sugar and better-for-you portfolio (Gatorade Zero, baked snacks, Quaker) relative to competitors more concentrated in full-calorie products.
By the Numbers
- Forward P/E of 7.05x vs trailing 18.6x implies consensus expects EPS to roughly double from $1.13 trailing to $8.55 estimated, suggesting the trailing figure reflects one-time charges or restructuring costs that massively depressed reported earnings.
- FCF conversion is healthy at 88% of net income, and FCF grew 44.8% YoY, the fastest rate in at least five years, while the 3Y CAGR of 11.4% confirms this is acceleration, not a one-time bounce.
- Negative cash conversion cycle of -108 days means PepsiCo collects from customers and turns inventory far faster than it pays suppliers (DPO of 206 days), effectively using vendor financing to fund operations at zero cost.
- SBC/revenue at just 0.33% is negligible for a company this size, meaning virtually none of the reported margin is inflated by non-cash compensation. Shares outstanding declined 0.16% YoY, confirming buybacks exceed dilution.
- International Beverages Franchise segment operating profit surged 21% YoY on just 2.4% revenue growth, indicating significant margin expansion in a capital-light franchise model that should carry higher incremental returns.
Risk Factors
- PBNA segment operating profit collapsed 52.7% YoY to $1.09B despite revenue growing 1.5%. This is PepsiCo's largest revenue segment at $28.2B, so margin compression here (from 8.3% to 3.9%) is a serious drag on consolidated profitability.
- Tangible book value per share is negative $8.88, with intangibles/goodwill comprising 30.5% of total assets. The 8.8x P/B multiple is entirely supported by brand value and goodwill, creating impairment risk if any segment underperforms structurally.
- Total company organic volume declined 2% for the second consecutive year while net pricing contributed +4%, meaning all organic revenue growth is pricing-driven. PFNA volumes fell 2% and PBNA volumes fell 3.5%, signaling consumer pushback in core North American markets.
- FCF payout ratio at 84.3% leaves minimal cushion for the 3.96% dividend yield. With $42.5B net debt (2.27x EBITDA) and a current ratio below 1.0 at 0.93, there is limited flexibility to simultaneously maintain dividends, service debt, and invest in growth.
- EMEA organic volume swung from +2% to -3% YoY, even as net pricing accelerated to +9%. This price-volume tradeoff suggests PepsiCo is pushing pricing beyond what consumers will absorb, risking share loss to private label in a key growth region.
The Procter & Gamble Company (NYSE: PG)
$143.71
Overall Grade6.4 / 10
The Procter & Gamble Company (P&G) is one of the world's largest and most prominent consumer packaged goods companies, operating globally across approximately 70 countries and selling products in over 180 countries and territories. The company's business model focuses on providing branded consumer goods of superior quality and value, leveraging extensive research and development, marketing, and a vast global supply chain...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E22.2
P/B6.3
P/S3.9
P/FCF22.5
FCF Yield+4.4%
Growth & Outlook
Rev Growth (YoY)+3.3%
EPS Growth (YoY)+1.7%
Revenue 5yr+2.7%
EPS 5yr+3.8%
FCF 5yr-1.5%
Fundamentals
Market Cap$332.3B
Dividend Yield3.0%
Operating Margin+22.7%
ROE+30.3%
Interest Coverage22.5x
Competitive Edge
- P&G's category leadership (Tide, Pampers, Gillette, Crest, Dawn) creates retailer dependency. Walmart, Costco, and Target cannot credibly threaten to delist these brands, giving P&G pricing power and shelf space advantages that private label cannot replicate.
- The 2017 portfolio restructuring that shed 100+ brands to focus on 65 core brands in 10 categories was a rare example of corporate self-discipline. This concentration enables higher R&D and marketing spend per brand, widening the gap against smaller competitors.
- P&G's direct-to-consumer and digital marketing capabilities have improved materially. The shift from mass TV advertising to targeted digital spend improves marketing ROI and reduces the historical advantage that scale in media buying once provided to competitors like Unilever.
- Distribution infrastructure across 180+ countries creates a compounding advantage. New product launches (like Tide Power Pods or Always Discreet) can be pushed through existing retail relationships globally, dramatically lowering go-to-market costs versus challengers.
By the Numbers
- Negative cash conversion cycle of -39 days means P&G collects from customers and turns inventory before paying suppliers (DPO 132 days vs DIO 67 + DSO 26). This is a working capital machine that self-funds growth.
- FCF-to-net-income ratio of 0.94x with OCF-to-net-income at 1.21x confirms high earnings quality. The gap between the two (22.5% capex-to-OCF) is modest for a company reinvesting in manufacturing at scale.
- Total shareholder yield of 5.06% (3% dividend + 1.2% buyback + 0.8% debt paydown) is compelling for a defensive staple. Share count declined 0.66% last year, meaning buybacks are genuinely retiring shares, not just offsetting the 0.6% SBC-to-revenue dilution.
- Fabric & Home Care EBT margins expanded from 20.8% in FY2022 to 24.9% in FY2024, a 400bps improvement over two years. This segment alone generates $7.3B in pre-tax income, roughly 35% of total segment profits.
- Health Care segment has delivered four consecutive years of EBT growth (5.4%, 6.6%, 7.1%, 0.4%), with margins expanding from 24.2% to 25.4%. This is the most consistent profit compounder in the portfolio.
Risk Factors
- Organic sales growth has decelerated from 7% in FY2022-23 to 4% to 2% to 1% in FY2026. This is a clear volume and pricing exhaustion trend. The pricing lever that drove post-COVID growth is spent.
- FCF growth 3Y and 5Y CAGRs are both negative (-0.7% and -1.3%) despite positive revenue growth, meaning capital intensity is rising. Capex-to-depreciation of 1.4x confirms P&G is spending well above maintenance levels, compressing free cash flow generation.
- Beauty segment EBT has declined three consecutive years (from $4.0B to $3.5B), with margins compressing from 26.7% to 21.7% in FY2026. Revenue grew 7.1% in FY2026 but EBT grew only 0.6%, signaling heavy promotional spending or cost inflation in SK-II and prestige lines.
- Tangible book value per share is negative at -$3.57, driven by intangibles comprising 49.6% of total assets and goodwill at 32.6%. The $54B in intangibles and goodwill from Gillette and other acquisitions creates meaningful impairment risk if brand premiums erode.
- PEG ratio of 3.64 is extremely stretched. With EPS growing at roughly 3.2-3.5% CAGR and the stock trading at 22x trailing earnings, you are paying a significant premium per unit of growth relative to the broader market.
Brookfield Asset Management Ltd. (NYSE: BAM)
$47.41
Overall Grade6.2 / 10
Brookfield Asset Management Ltd. operates as one of the world's largest alternative asset managers, providing investment products to institutional and retail clients globally, including pension plans, sovereign wealth funds, and endowments...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E26.0
P/B9.5
P/S12.5
P/FCF30.6
FCF Yield+3.3%
Growth & Outlook
Rev Growth (YoY)+31.9%
EPS Growth (YoY)+14.7%
Revenue 5yr-
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$104.4B
Dividend Yield4.2%
Operating Margin+61.6%
ROE+26.8%
Interest Coverage20.5x
Competitive Edge
- BAM's five-pillar structure (renewables, infrastructure, PE, real estate, credit) creates a natural cross-selling engine. Institutional LPs allocating to one strategy often expand across others, lowering customer acquisition costs and increasing wallet share over time.
- The insurance channel via Brookfield Reinsurance provides permanent, cost-advantaged capital that competitors like Apollo took years to build. This captive capital source reduces fundraising cyclicality and locks in long-duration fee streams.
- BAM operates in real assets (infrastructure, renewables, real estate) where deal complexity, regulatory expertise, and operational capability create genuine barriers to entry. Blackstone and KKR compete, but few managers can operate a hydroelectric dam or data center.
- The energy transition megatrend gives BAM a structural fundraising tailwind. With $67B in renewable power and transition FBC and governments globally mandating decarbonization, this is a multi-decade capital deployment opportunity with limited competition at scale.
- Geographic diversification is genuine: 49% of AUM sits outside the U.S., with meaningful European ($264B) and Asia-Pacific ($159B) exposure. This reduces single-country regulatory risk and opens fundraising channels that U.S.-centric peers cannot easily replicate.
By the Numbers
- Fee-related earnings grew 21.9% YoY in FY2025, accelerating sharply from the 9.6% pace in FY2024. This is the fastest FRE growth since the spin-off and signals operating leverage is finally kicking in as fee-bearing capital scales past $600B.
- Credit & Other fee-bearing capital has compounded from $132B to $279B in three years, now representing 46% of total fee-bearing capital. This segment's 21.2% revenue growth in consecutive years shows the Oaktree integration and insurance channel are producing durable, not one-time, momentum.
- SBC/revenue at just 2.4% is remarkably low for an asset manager of this scale. With $140M in TTM SBC against $872M in buybacks, management is returning roughly 6x more via repurchases than it is diluting, a rare and shareholder-friendly ratio.
- FRE margin (fee-related earnings / total fee revenue) expanded to 54.6% in FY2025 from 52.2% in FY2024, demonstrating that incremental fee revenue is dropping to the bottom line at a higher rate. SG&A/revenue of just 8.5% confirms the cost structure is highly scalable.
- Current P/E of 28.4x and EV/EBITDA of 23.7x both sit meaningfully below 3-year historical averages of 35.4x and 28.8x respectively. The stock is trading at roughly a 20% discount to its own history despite accelerating FRE growth, a clear disconnect.
Risk Factors
- Payout ratio of 117.7% and FCF payout ratio of 142.8% mean BAM is distributing more than it earns on both an accounting and cash basis. The $2.05/share dividend requires either parent subsidies or balance sheet drawdowns to sustain at current earnings levels.
- Forward P/E of 36.0x is actually higher than trailing P/E of 28.4x, which is unusual and suggests consensus Y1 EPS of $1.86 may include non-recurring items depressing the forward number. Investors paying the forward multiple are not getting a growth discount.
- Quick ratio of 0.56 is well below 1.0, indicating limited liquid assets relative to near-term liabilities. For an asset-light manager, this is surprisingly tight and suggests the balance sheet is being run aggressively to maximize returns to the parent.
- Real estate fee-bearing capital stagnated for two years (flat in FY2024, only +8.6% in FY2025) while the segment still represents 17% of total FBC. With office and commercial real estate under secular pressure, this $102B pool could face redemption risk.
- Revenue per share of $3.54 against a stock price of $48.85 yields a P/S of 13.6x, which is extreme even for asset managers. If fee rates compress by even 5-10bps due to competitive pressure, the impact on this valuation multiple would be severe.
Altria Group, Inc. (NYSE: MO)
$68.67
Overall Grade6.2 / 10
Altria Group, Inc. operates through several subsidiaries, including Philip Morris USA, U.S...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E15.2
P/B-45.0
P/S5.9
P/FCF13.2
FCF Yield+7.6%
Growth & Outlook
Rev Growth (YoY)+0.9%
EPS Growth (YoY)-8.3%
Revenue 5yr-0.7%
EPS 5yr+14.1%
FCF 5yr+7.7%
Fundamentals
Market Cap$114.9B
Dividend Yield6.5%
Operating Margin+53.7%
ROE-273.8%
Interest Coverage10.0x
Competitive Edge
- Marlboro commands ~42% of U.S. premium cigarette share, creating distribution lock-in at retail. Convenience stores allocate shelf space based on Marlboro velocity, giving Altria structural advantages in trade promotion and placement.
- NJOY holds one of only a handful of FDA-authorized ENDS (electronic nicotine delivery system) marketing orders. This regulatory moat effectively blocks most competitors from legally marketing flavored or novel vapor products in the U.S.
- The Master Settlement Agreement and federal excise tax structure create a regulatory barrier that protects incumbents. New cigarette entrants face per-stick cost disadvantages of $0.40 or more versus established manufacturers.
- Altria's direct store delivery network for smokeable products is nearly impossible to replicate. This distribution infrastructure gives new products like on! and NJOY immediate access to 200,000+ retail locations without incremental fixed cost.
By the Numbers
- FCF-to-net-income conversion of 1.07x confirms earnings quality is genuine, not accounting-driven. With capex at just 3% of operating cash flow, virtually all cash generated drops to shareholders. This is a textbook cash cow.
- Smokeable products operating income grew 1.5% YoY on revenue that declined 3.4%, meaning pricing power expanded operating margins by roughly 250bps. Altria is shrinking its way to higher profits per stick, a rare and powerful dynamic.
- Total shareholder yield of 7.9% (6.3% dividend + 0.8% buyback + 1.4% debt paydown) is among the highest in Consumer Staples. The three-pronged return structure gives management flexibility to shift allocation as conditions change.
- Oral tobacco operating income surged 26.2% YoY after a 15.9% decline the prior year, signaling the on! investment phase is maturing. The segment's operating margin jumped from ~52% to ~65%, approaching the smokeable segment's profitability.
- ROIC of 27.9% against a cost of debt implied at roughly 9.5% (interest coverage of 10.5x on $24.6B debt) creates massive economic value added. The spread between returns and capital cost is wider than most consumer staples peers.
Risk Factors
- Marlboro shipment volumes declined 12.2% YoY in FY2025, accelerating from the 9% decline in FY2024. This is the steepest volume erosion in the dataset, and pricing power must offset an increasingly steep hill each year.
- Discount cigarette shipments surged 41.3% YoY after three consecutive years of 18-30% declines. This reversal suggests trade-down pressure from consumers or competitive repositioning that could compress blended revenue per stick.
- The 'Other Operating Income' line ballooned to negative $2.5B in FY2025 from negative $414M in FY2024. This likely reflects NJOY-related impairments or restructuring charges, masking the true cost of the smoke-free transition.
- Negative book value of negative $1.91 per share and negative tangible book of negative $12.43 per share means the entire equity cushion has been consumed by buybacks and write-downs. Any large impairment directly threatens debt covenants.
- on! shipment volume growth decelerated sharply from 40.2% in FY2024 to 10.9% in FY2025, and the most recent quarter showed a 19% QoQ decline. The growth engine in oral nicotine may be plateauing earlier than bulls expect.
The Home Depot, Inc. (NYSE: HD)
$308.93
Overall Grade5.6 / 10
The Home Depot, Inc. operates as the world's largest specialty retailer of home and garden improvement products...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E23.2
P/B19.9
P/S2.0
P/FCF21.9
FCF Yield+4.6%
Growth & Outlook
Rev Growth (YoY)+2.5%
EPS Growth (YoY)-2.9%
Revenue 5yr+3.2%
EPS 5yr+0.1%
FCF 5yr+4.4%
Fundamentals
Market Cap$305.0B
Dividend Yield3.0%
Operating Margin+12.4%
ROE+104.3%
Interest Coverage8.7x
Competitive Edge
- The SRS Distribution acquisition transforms HD's addressable market by adding a $50B+ specialty trade distribution channel (roofing, landscaping, pool supplies) that bypasses the store format entirely, giving HD direct access to professional contractors who previously bought elsewhere.
- HD's pro customer segment generates roughly 50% of revenue with higher average tickets and repeat purchase frequency. The pro ecosystem (credit programs, dedicated sales reps, jobsite delivery) creates switching costs that Lowe's has struggled to replicate despite years of investment.
- Home improvement is structurally supported by an aging U.S. housing stock (median home age ~40 years) and chronic underbuilding since 2008. Deferred maintenance spending is non-discretionary and accumulates, creating a demand backlog that eventually converts regardless of macro conditions.
- HD's supply chain investment, over 100M sq ft of warehouse and distribution space, enables same-day and next-day delivery for pros. This logistics infrastructure took a decade and billions to build, creating a barrier that pure-play e-commerce competitors like Amazon cannot easily replicate for heavy, bulky building materials.
- Exclusive brand partnerships (Ryobi, Milwaukee via TTI, Husky, HDX) drive store traffic and margin. These vendor relationships, built over decades, are deeply embedded in co-marketing and product development cycles that competitors cannot quickly replicate.
By the Numbers
- FCF-to-net-income conversion of 1.06x confirms high earnings quality. With SBC at just 0.33% of revenue ($560M on $165B), reported earnings closely approximate cash economics, unlike many large-caps where SBC inflates margins by 3-5 percentage points.
- ROIC of 19.5% against a weighted average cost of capital likely near 8-9% implies the business creates roughly $0.10 of economic value per dollar of invested capital. This spread has persisted for years, signaling a durable competitive advantage.
- Inventory turnover of 4.26x with 86 days inventory on hand is well-managed for a big-box retailer carrying 35,000+ SKUs. The cash conversion cycle of 57 days, anchored by DPO of 43 days, shows HD uses supplier financing effectively to fund working capital.
- Comparable sales turned positive at +2.2% LTM after two consecutive years of negative comps (-3.2% FY2024, -1.8% FY2025), signaling the housing-related demand trough is likely behind us. Customer transactions remain soft at -2.4%, but average ticket growth is compensating.
- Capex-to-depreciation ratio of 0.85x means HD is spending less than its depreciation charge, freeing up cash. Capex-to-OCF of just 19.6% leaves over 80% of operating cash flow available for dividends, buybacks, and debt service.
Risk Factors
- Tangible book value per share is negative $33.53, meaning the entire $337B market cap rests on intangible assets (30.5% of total assets) and future earnings power. Goodwill at 20.9% of assets reflects the SRS Distribution acquisition, creating impairment risk if pro integration stumbles.
- EPS has declined at a -2.8% 3-year CAGR and -0.9% 5-year CAGR despite revenue growing at 3.2% and 2.8% respectively. Rising interest expense from $62.6B in total debt is consuming the operating leverage that historically dropped to the bottom line.
- Net debt-to-EBITDA of 2.39x with debt-to-equity of 3.39x and total debt-to-capital at 100% leaves zero equity cushion. Interest coverage at 10.5x is adequate today, but any EBITDA compression from a housing downturn would tighten this ratio quickly.
- The PEG ratio of 3.95 is extremely elevated, implying the market is paying nearly 4x the growth rate for earnings. With forward EPS estimates showing only 6% growth from $14.23 trailing to $15.10 in Y1, the valuation assumes a reacceleration that hasn't materialized yet.
- Buyback yield is negative at -0.1%, meaning share count actually increased 0.13% YoY. Despite the company's reputation as a capital returner, the SRS acquisition has paused meaningful share repurchases, and dilution from SBC is no longer being offset.
Prologis, Inc. (NYSE: PLD)
$135.34
Overall Grade5.2 / 10
Prologis Inc. is a global leader in industrial real estate, specializing in the ownership, development, and management of logistics facilities...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E30.2
P/B2.4
P/S13.8
P/FCF-275.0
FCF Yield-0.4%
Growth & Outlook
Rev Growth (YoY)+7.4%
EPS Growth (YoY)+21.7%
Revenue 5yr+15.4%
EPS 5yr+16.6%
FCF 5yr-
Fundamentals
Market Cap$125.4B
Dividend Yield3.2%
Operating Margin+38.4%
ROE+7.7%
Interest Coverage3.4x
Competitive Edge
- Prologis controls ~1.2B sq ft of logistics space in irreplaceable infill locations near major population centers. Zoning restrictions and land scarcity in these markets create a physical barrier to entry that no competitor can replicate at scale.
- The strategic capital platform (co-investment vehicles) allows Prologis to earn fees on $100B+ of AUM while retaining operational control. This asset-light income stream has higher returns on equity than direct ownership, even during its current cyclical trough.
- Customer base spans Amazon, FedEx, DHL, and thousands of mid-market tenants across 19 countries. No single tenant exceeds ~6% of rent, and e-commerce structural demand for last-mile logistics creates a secular floor under occupancy.
- Embedded rent growth from mark-to-market on below-market leases is estimated at 30-40% across the portfolio. As leases roll over the next 3-5 years, this provides a visible, contractual growth runway independent of new development.
- Data center conversion optionality is emerging as a real asset. Prologis owns large-format industrial sites with power infrastructure that can be repurposed for AI/cloud data centers, creating a valuation catalyst not yet priced into the stock.
By the Numbers
- Core FFO grew 4.8% YoY to $5.56B in FY2025 after a flat FY2024, translating to roughly $5.96/share. At $139.97, the stock trades at ~23.5x FFO, which is more reasonable than the misleading 35x GAAP P/E that distorts REIT analysis.
- Rental revenue grew 8.6% YoY to $8.16B, accelerating from the prior year's 10.2% growth on a much larger base. Property NOI margins remain strong at ~76%, and same-property NOI growth is the core earnings engine here.
- Occupancy stabilized at 95.8% after declining from 98.2% in FY2022. The quarterly data shows sequential improvement from 95.3% to 95.8%, suggesting the trough may be in. This is the single most important leading indicator for rental revenue acceleration.
- Debt-to-equity at 0.60 is conservative for an industrial REIT, and interest coverage at 6.0x provides adequate cushion. The 7.8/10 Risk grade aligns with a balance sheet that can absorb a prolonged soft patch without dividend risk.
- SG&A at just 5.4% of revenue reflects extreme operating efficiency for a company managing 5,440 properties globally. SBC at 2.2% of revenue ($193M) is modest relative to the $5.56B FFO base, causing minimal dilution.
Risk Factors
- Net debt/EBITDA at 5.5x is elevated even by REIT standards. With $33.8B in net debt and only $848M in unlevered FCF, the company would need 40+ years of current FCF to delever. Capital recycling and asset sales are essential, not optional.
- The FCF payout ratio of 16.4x (vs. earnings payout of 1.03x) reveals massive capex intensity. Capex consumed 95.3% of operating cash flow, meaning the dividend is funded by debt and capital markets access, not organic free cash flow.
- Strategic Capital revenue declined 11.8% YoY to $592M, with NOI down 15.3%. This segment contributed $1.2B just two years ago. The fee stream from co-investment vehicles is shrinking as transaction volumes remain depressed.
- Forward P/E of 41.5x is higher than trailing 35x, implying consensus expects GAAP EPS to decline to $3.38 in Y1 before recovering. The market is pricing in a recovery that hasn't started yet on a GAAP basis.
- Current ratio at 0.51 means short-term liabilities exceed current assets by nearly 2:1. For a REIT this is manageable through revolving credit facilities, but it creates refinancing dependency in a higher-rate environment.
The U.S. dividend universe rewards patience differently than the TSX does. Up here, you buy a bank or a pipeline and you’re essentially betting on stability. That’s fine. But the names in this list give you something Canadian dividend stocks rarely offer: optionality. A semiconductor company reinvesting in capacity. A gold miner benefiting from a commodity cycle. An energy producer with discipline around capital returns. These aren’t just income vehicles. They’re businesses where the dividend is a byproduct of actual growth, not a substitute for it.
That’s the lens I’d use here. Which of these companies will be earning meaningfully more in five years than they are today? The dividend is just the receipt that proves it’s happening. If the earnings aren’t growing, the yield is just your own money coming back to you in slow motion.
